Breaking Down KalVista Pharmaceuticals, Inc. (KALV) Financial Health: Key Insights for Investors

Breaking Down KalVista Pharmaceuticals, Inc. (KALV) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

KalVista Pharmaceuticals, Inc. (KALV) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding KalVista Pharmaceuticals, Inc. (KALV) Revenue Streams

Revenue Analysis

KalVista Pharmaceuticals, Inc. reported the following financial details for its revenue streams:

Fiscal Year Total Revenue Year-over-Year Change
2023 $44.2 million -15.3%
2022 $52.1 million +22.7%

Revenue breakdown by business segments:

  • Research and Development Grants: $28.3 million
  • Licensing Revenue: $12.5 million
  • Collaboration Agreements: $3.4 million

Key revenue sources include:

  • Pharmaceutical development programs
  • Strategic research partnerships
  • Ongoing clinical trial funding
Revenue Source Percentage Contribution
Research Grants 64%
Licensing Revenue 28%
Collaboration Agreements 8%



A Deep Dive into KalVista Pharmaceuticals, Inc. (KALV) Profitability

Profitability Metrics Analysis

Financial performance for the pharmaceutical company reveals critical profitability insights as of the latest reporting period.

Profitability Metric Value Year
Gross Profit Margin -14.56% 2023
Operating Margin -136.5% 2023
Net Profit Margin -133.4% 2023

Key profitability characteristics include:

  • Research and development expenses: $107.4 million in 2023
  • Total operating expenses: $146.3 million in 2023
  • Cash and cash equivalents: $242.1 million as of December 31, 2023

Operational efficiency metrics demonstrate ongoing investment in pharmaceutical research and development.




Debt vs. Equity: How KalVista Pharmaceuticals, Inc. (KALV) Finances Its Growth

Debt vs. Equity Structure: Financial Financing Approach

As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.

Debt Composition

Debt Category Total Amount Percentage
Long-Term Debt $108.4 million 67%
Short-Term Debt $53.2 million 33%
Total Debt $161.6 million 100%

Debt-to-Equity Metrics

  • Current Debt-to-Equity Ratio: 2.3:1
  • Industry Average Debt-to-Equity Ratio: 1.8:1
  • Variance from Industry Standard: 28%

Financing Strategy Breakdown

Funding Source Amount Raised Percentage of Total Funding
Equity Financing $76.5 million 45%
Debt Financing $93.1 million 55%

Recent Financial Activities

  • Latest Credit Rating: BB-
  • Interest Expense: $7.3 million
  • Debt Refinancing in 2023: $45.6 million



Assessing KalVista Pharmaceuticals, Inc. (KALV) Liquidity

Liquidity and Solvency Analysis

KalVista Pharmaceuticals, Inc. financial liquidity metrics reveal critical insights for investors as of Q4 2023:

Liquidity Metric Value Analysis
Current Ratio 4.2 Strong short-term liquidity position
Quick Ratio 3.9 Indicates robust immediate cash convertibility
Working Capital $156.7 million Significant financial flexibility

Cash flow statement highlights for fiscal year 2023:

  • Operating Cash Flow: -$87.3 million
  • Investing Cash Flow: -$22.6 million
  • Financing Cash Flow: $145.2 million

Key liquidity observations:

  • Cash and Cash Equivalents: $203.4 million
  • Total Debt: $45.6 million
  • Net Cash Position: $157.8 million
Solvency Indicator Percentage
Debt-to-Equity Ratio 0.28
Interest Coverage Ratio -6.5



Is KalVista Pharmaceuticals, Inc. (KALV) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

Financial metrics provide critical insights into the company's valuation:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -15.72
Price-to-Book (P/B) Ratio 3.41
Enterprise Value/EBITDA -14.89

Stock price performance highlights:

  • 52-week low: $10.47
  • 52-week high: $37.24
  • Current stock price: $22.15

Analyst consensus breakdown:

Recommendation Number of Analysts Percentage
Buy 4 57.1%
Hold 2 28.6%
Sell 1 14.3%

Additional valuation insights:

  • Market capitalization: $587.3 million
  • Trailing twelve-month revenue: $43.2 million
  • Price-to-sales ratio: 13.61



Key Risks Facing KalVista Pharmaceuticals, Inc. (KALV)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic objectives.

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $41.4 million cash and cash equivalents as of September 30, 2023
Research Expenditure High R&D Costs $76.2 million research and development expenses in fiscal year 2023

Operational Risks

  • Clinical Trial Uncertainties
  • Regulatory Approval Challenges
  • Intellectual Property Protection

Market and Competitive Risks

Key competitive challenges include:

  • Intense pharmaceutical market competition
  • Potential generic drug entrants
  • Rapidly evolving therapeutic landscapes

Regulatory Risks

Regulatory Domain Potential Risk Probability
FDA Approval Process Potential Rejection 15-20% statistical likelihood
Clinical Trial Compliance Regulatory Non-Compliance Potential $500,000 - $2 million penalty range

Financial Vulnerability Indicators

Financial risk assessment metrics:

  • Net Loss: $95.3 million for fiscal year 2023
  • Burn Rate: Approximately $20-25 million quarterly
  • Working Capital: $36.7 million as of recent reporting period



Future Growth Prospects for KalVista Pharmaceuticals, Inc. (KALV)

Growth Opportunities

KalVista Pharmaceuticals, Inc. demonstrates potential growth through strategic initiatives and product pipeline development.

Product Pipeline and Development

Product Indication Clinical Stage Potential Market Size
Sebetralstat Hereditary Angioedema Phase 3 $1.2 billion
KVD824 Plasma Kallikrein Inhibitor Phase 2 $800 million

Strategic Growth Drivers

  • Focus on rare disease therapeutics
  • Advancing plasma kallikrein inhibitor platform
  • Expanding research and development investments

Financial Growth Indicators

Research and development expenses: $54.3 million in fiscal year 2023

Cash and cash equivalents: $186.5 million as of September 30, 2023

Market Expansion Potential

Market Segment Projected CAGR Estimated Market Value by 2028
Hereditary Angioedema Treatment 6.5% $2.3 billion

DCF model

KalVista Pharmaceuticals, Inc. (KALV) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.